Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
129.8 EUR | -0.19% | +1.61% | +64.45% |
Apr. 11 | Berenberg Reiterates UCB's Purchase Rating, Raises PT | MT |
Apr. 11 | UCB : Berenberg, Buy, raises its price target | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- With an expected P/E ratio at 62.15 and 28.76 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.68 times its current sales, is high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+64.45% | 26.66B | A | ||
+0.82% | 91.94B | A- | ||
-1.32% | 38.74B | A- | ||
-12.88% | 32.82B | B- | ||
-16.31% | 15.32B | C | ||
-11.38% | 11.65B | D+ | ||
+173.10% | 10.37B | D | ||
-49.84% | 10.12B | B | ||
+4.04% | 9.06B | B+ | ||
-16.26% | 7.46B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- UCB Stock
- Ratings UCB